The global market for induced pluripotent stem cells (iPSCs) was estimated to total $853 million in 2012, and close to $1.2 billion in 2013, averaging 40% growth. The market is expected to reach $2.9 billion in 2018, an estimated compound annual growth rate (CAGR) of 19.7% for the five-year period 2013 to 2018.
This report provides:
Download Report Overview
SCOPE OF REPORT
This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered. For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelia cells, and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of World. Research and market trends are also analyzed by analyzing the funding, patent publications and sales trends of major players in the field.
Mike Fan has more than 20 years experience in biotech research and development (R&D) and life science marketing from academics and industry. Dr. Fan has a broad range of experience in chemical, biochemical and biomedical areas, including biochemical engineering (e.g., microbial fermentation, biocatalysis, metabolic engineering), chemical synthesis, biomedical engineering (e.g., biomedical instrument development, microarray technologies), molecular genetics, genetic analysis, drug discovery, cancer biology, cancer immunology, targeted therapy and stem cell research. He holds a PhD in Chemical Engineering and a Master of Business Administration focusing on Marketing.